Lifecore Biomedical
LFCR
78 hedge funds and large institutions have $136M invested in Lifecore Biomedical in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 10 closing their positions.
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
87% more call options, than puts
Call options by funds: $954K | Put options by funds: $509K
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
13% more funds holding
Funds holding: 69 → 78 (+9)
7.12% more ownership
Funds ownership: 65.45% → 72.57% (+7.1%)
3% more capital invested
Capital invested by funds: $132M → $136M (+$3.72M)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
3C
325 Capital
New York
|
+$8.38M |
| 2 |
Morgan Stanley
New York
|
+$5.43M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.19M |
| 4 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$1.21M |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$965K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.43M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.36M |
| 3 |
CSC
Cove Street Capital
El Segundo,
California
|
-$1.36M |
| 4 |
HT
HAP Trading
New York
|
-$1.24M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$758K |
LFCR Hedge Fund Activity: Q4 2023 in Review
78 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2023, worth a combined $136M — up 2.8% from $132M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new LFCR positions and 10 closed out — a net gain of 9 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was 325 Capital, opening a new position worth an estimated $8.38M. The largest seller was Millennium Management, cutting an estimated $2.43M.
- 78 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2023, up from 69 in Q3 2023.
- Funds reported $136M of Lifecore Biomedical stock for Q4 2023, up 2.8% quarter-over-quarter.
- 19 funds opened new Lifecore Biomedical positions in Q4 2023 and 10 closed out, a net change of +9 holders.
- The largest Lifecore Biomedical buyer in Q4 2023 was 325 Capital, an estimated $8.38M added.
- The largest Lifecore Biomedical seller in Q4 2023 was Millennium Management, an estimated $2.43M sold.
Based on aggregated 13F filings for Q4 2023.